
Three Connected Technologies Are Transforming Type 1 Diabetes Care—Especially for Teens
Continuous glucose monitoring, automated insulin delivery, and remote care are working together to help adolescents achieve better blood sugar control and fewer dangerous lows. Here's what the latest research shows.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Hybrid closed-loop insulin delivery systems improve time in range, lower HbA1c, and reduce severe lows and ketoacidosis in both children and adults
- Continuous glucose monitoring provides real-time data that enables better decision-making when combined with education and support
- Remote care models using continuous data can achieve similar glycemic outcomes to in-person visits while improving access and emotional support
- Semaglutide, a medication originally developed for type 2 diabetes, showed promise in a trial of adults with type 1 diabetes and obesity on automated insulin delivery
- Access barriers remain significant—socioeconomic inequities, alarm fatigue, and uneven healthcare system adoption limit who can benefit from these advances
A Technology Trio Changing the Game
Type 1 diabetes management in adolescents has long been complicated by hormonal changes and behavioral factors that make blood sugar unpredictable. But three interconnected technologies are reshaping what's possible: continuous glucose monitoring (CGM), automated insulin delivery (AID) systems, and remote care.
These aren't separate tools—they work best together. CGM gives real-time glucose readings. AID systems (also called hybrid closed-loop or artificial pancreas devices) use those readings to automatically adjust insulin delivery. And remote care leverages the continuous data stream to let healthcare teams follow patients between traditional office visits, offering personalized support without requiring as many in-person appointments.
What the Evidence Shows About Automated Insulin Delivery
Hybrid closed-loop systems have consistently delivered results across multiple studies. They increase time in range (the percentage of time glucose stays in a healthy target zone), reduce HbA1c (a measure of average blood sugar over three months), and lower risks of severe hypoglycemia and diabetic ketoacidosis (DKA)—a life-threatening complication.
The evidence spans age groups too. These systems have been validated in children as young as 1 year old, suggesting that earlier adoption may be an option for families. The benefits appear in both carefully controlled clinical trials and real-world studies, meaning the improvements hold up when people use these devices at home.
Remote Care: Bringing Support Home
Remote care models represent a shift in how diabetes is monitored. Instead of relying solely on quarterly or annual office visits, healthcare teams can review continuous glucose data and adjust care plans from afar. Early research shows that glycemic outcomes from remote care approach those achieved with traditional in-person appointments.
Beyond numbers, remote monitoring improves access for people who live far from diabetes clinics or face transportation challenges. It can also enhance psychosocial support—offering timely check-ins and guidance when someone is struggling with managing their condition.
New Medications May Have a Role
Semaglutide, a medication approved for type 2 diabetes and weight loss, recently showed promise in a trial involving 72 adults with type 1 diabetes who were already using automated insulin delivery. Over 26 weeks, participants taking semaglutide achieved better blood sugar control in range and lost more weight than those on AID alone. Notably, there were no cases of diabetic ketoacidosis, and severe low blood sugar events were rare in both groups.
This research is early, but it suggests that adjunctive therapies—medications added alongside insulin—may eventually become part of the management toolkit for certain patients. The same applies to other emerging options being studied, such as sodium glucose cotransporter-1 inhibitors and glucagon-like peptide 1 receptor agonists.
Real Progress, With Gaps Still to Close
Despite these advances, significant barriers remain. Access to CGM and AID systems is unequally distributed. Many people in under-resourced parts of the world still lack access to basic supplies like insulin, syringes, and blood glucose monitoring—let alone cutting-edge technologies.
Within wealthier healthcare systems, other challenges persist: alarm fatigue (when too many alerts wear people down), gaps in how systems are rolled out across hospitals and clinics, and the need for stronger evidence on long-term psychosocial outcomes. Future research priorities include fully closed-loop systems that require even less user input, algorithms that better account for exercise and illness, and strategies to ensure equitable access across all communities.
Evidence label
Origin: frontiersin.org (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Our own writing on the same ground.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Research summaryCure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Research summaryCure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Research summaryCure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies